PLUS

HEADLINES TREATMENT REGIMENS FROM THE ADVISORY BOARD PUBLISHERS ALLIANCE TOOLS MULTIMEDIA CME

Study Identifies 'Spin' and 'Bias' in Reported Results of Phase 3 Randomized Breast Cancer Trials

Share this article:

(ChemotherapyAdvisor) – A high proportion of published studies of phase 3 randomized clinical trials for women with breast cancer demonstrate bias when reporting outcomes with negative primary end points and, when end points are positive, toxicity is under-reported, the first study to investigate this association reported in Annals of Oncology, published online January 10, 2013.

In one-third of trials failing to show a statistically significant benefit for the study treatment, the studies focused on other, less important outcomes in an attempt to put a positive interpretive “spin” on the results, noted Ian Tannock, MD, PhD, Division of Medical Oncology and Hematology at the Princess Margaret Hospital, Toronto, Ontario, Canada, and colleagues.

And, in two-thirds of the reports, only 32% of trials that showed a significant benefit for the study treatment reported frequency of grade 3 or 4 toxicities in the abstract.

“Better and more accurate reporting is urgently needed,” stated Dr. Tannock. “Journal editors and reviewers, who give their expertise on the topic, are very important in ensuring this happens. However, readers also need to critically appraise reports in order to detect potential bias. We believe guidelines are necessary to improve the reporting of both efficacy and toxicity.”

A PUBMED search of randomized phase 3 trials conducted from January 1995 to August 2011 found 164 that were eligible for inclusion in the analysis.

The investigators defined bias as “inappropriate reporting of the primary end point and toxicity, with emphasis on reporting of these outcomes in the abstract” and spin as “the use of words in the concluding statement of the abstract to suggest that a trial with a negative primary end point was positive based on some apparent benefit shown in one or more secondary end points.”

They found that 54 (33%) trials showed bias in reporting of the primary end point “and used spin in attempts to conceal that bias,” the authors wrote. In 92 trials with a negative primary end point, 59% used secondary end points to suggest benefit.

Biased reporting of adverse events occurred in 110 papers (67%), with toxicities more likely to be under-reported if the primary end point was positive.

The source of funding for trials (industry or academic) was not associated with bias or spin in the reporting of results and toxicities, they concluded, and added that “trial registration does not necessarily remove bias in reporting outcomes, although it does make it easier to detect.”

Abstract

Share this article:

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Breast Cancer

For Patients With a Positive Sentinel Node in Breast Cancer, Radiotherapy is Comparable to Dissection

For Patients With a Positive Sentinel Node in ...

Radiotherapy of the axillary lymph node following a positive sentinel node effective approach in breast cancer.

In Breast Cancer Survivors, Depression Lingers

In Breast Cancer Survivors, Depression Lingers

Breast cancer survivors found more likely to need hospital care, antidepressants than cancer-free women.

Trastuzumab Plus Vinorelbine May Be an Effective Alternative for HER2-Positive Breast Cancer

Trastuzumab Plus Vinorelbine May Be an Effective Alternative ...

Trastuzumab and vinorelbine an effective alternative to standard taxane-based chemotherapy for HER2-positive breast cancer.